Geranyl tiglate is a geranium-like monoterpene ester found in several Pelargonium graveolens materials already represented in the AromaForge archive. The current public evidence base is strongest for identity, aroma description, occurrence in geranium oils, and a modern RIFM fragrance safety review. Direct standalone pharmacology is still limited, so the most defensible profile is as a distinctive floral-ester marker with safety data grounded mainly in read-across, TTC logic, and exposure modeling rather than human outcome trials.
Aroma and practical use
- Use the recorded geranium-like, fruity, rosy, sweet-herbaceous, lemony, rose-like, citrus descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
The 2025 RIFM fragrance safety assessment concluded that geranyl tiglate is not expected to be genotoxic, that skin sensitization can be managed with a NESIL of 4700 microg/cm2 derived from read-across, and that the material is not expected to be photoirritating or photoallergenic.
RIFM also states that repeated-dose, reproductive, and local respiratory exposures are below TTC thresholds for this Cramer Class I material.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
A public Pelargonium graveolens composition-and-fractions paper reported geranyl tiglate at 5.21% in crude oil and identified a fraction where geranyl tiglate and geranyl butanoate were major contributors.
The same paper attributes antibacterial effects to the oil and fractions as mixtures, so it supports occurrence more strongly than direct geranyl-tiglate bioactivity.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The archive's own Bourbon and Chinese geranium records place geranyl tiglate around 1-4%, confirming that it can be a meaningful secondary ester rather than just a trace analytical artifact.
These records align with the broader geranium-like odor descriptions in fragrance references.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedRIFM's current public assessment says geranyl tiglate is safe as described in that safety assessment and does not expect phototoxic or photoallergic behavior from the reviewed UV/Vis profile.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Key safety endpoints for geranyl tiglate rely on read-across and TTC rather than direct repeated-dose or reproductive NOAEL studies on the exact constituent.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct human clinical literature focused on isolated geranyl tiglate was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
expected ester hydrolysis to geraniol and tiglic acid
This is a chemistry-based inference from simple-ester behavior and the RIFM use of analog/read-across logic rather than a direct metabolism study on geranyl tiglate.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Direct constituent-specific pharmacology for isolated geranyl tiglate remains sparse compared with the safety and occurrence literature.
- Mechanistic handling is inferred from ester chemistry and read-across rather than direct ADME experiments on geranyl tiglate.
- This pass did not verify a standalone JECFA decision page with the same level of detail as the RIFM review, although PubChem and FDA-linked flavoring references indicate established flavouring status.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.